Clinical trials: 28 Day Mortality
Sepsis
Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis
The objective of this study is to demonstrate that rPAF-AH is safe and reduces 28 day all cause mortality in patients with severe sepsis.
- Trial name
- NCT00037687
- Testing
- rPAF-AH
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- ICOS Corporation